kidney issues with tirzepatide GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of disease. This new post-hoc analysis of SURPASS-CVOT's kidney outcomes shows greater kidney protection (#mounjaro) Tirzepatide and prevention of chronic

Read the full article: 5 things doctors want you to know before you start taking a GLP-1 washingtonpost.com To view or add a comment, sign in More Relevant Posts As broader and longer term experience with the use of the modern obesity medications rises, the importance of proper nutrition during therapy has become apparent

6?5, 8

I have 10 more to go

doi: 10.3389/fphar.2025.1551843 Received 26 December 2024 Accepted 09 June 2025 Published 02 July 2025 Volume 16 - 2025 Edited by Ting Shen, Yangzhou University, China Reviewed by Shuo Yuan, University of Virginia, United States Yan Hu, Second Affiliated Hospital of Dalian Medical University, China Updates Copyright 2025 Mao, Huang, Li, Sun, Zhang, Cheng, Zeng, Lei, Wang and Yao

Comparative effects of proximal and distal small intestinal glucose exposure on glycemia, incretin hormone secretion, and the incretin effect in health and type 2 diabetes

No peptide addresses aging in isolation, and the foundation of any protocol matters as much as the peptide itself